证券代码：300122 证券简称：智飞生物 公告编号：2025-49 重庆智飞生物制品股份有限公司 关于吸附无细胞百白破（组分）联合疫苗（成人及青少年用） 临床试验申请获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 智飞绿竹研发的青少年及成人组分百白破疫苗是新一代的无细胞百白破疫 苗，系采用单独纯化的百日咳有效组分，联合白喉、破伤风有效组分配制出的质 1 量均一的疫苗产品，适用于 7 岁及以上健康人群预防百日咳、白喉、破伤风。截 至目前，国内暂无可供青少年及成人使用的组分百白破疫苗获批上市，市场前景 广阔。 公司积极响应国家鼓励研发多联多价疫苗的号召，发挥技术创新优势，在研 管线中吸附无细胞百白破（组分）联合疫苗处于 III 期临床试验中，组分百白破 -Hib 四联疫苗已获得临床试验批准通知书。青少年及成人组分百白破疫苗临床试 验申请获得受理亦是公司聚焦创新技术、增强科研攻关的成果。若本项目进展顺 利，将进一步夯实公司多联疫苗矩阵布局，强化公司的市场竞争优势，为实现长 远目标奠定坚实基础。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日 ...

2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：重庆智飞生物制品股份有限公司 单位：万元 | 非经营性资金占 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核 算的会计科 | 2025 年期初占 | 年 月占 2025 1-6 用累计发生金额 | 年 2025 1-6 占用资金的利 | 月 2025 | 年 1-6 月偿 | 2025 年6 月末 | 占用 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 用 | | 关联关系 | 目 | 用资金余额 | （不含利息） | 息(如有） | | 还累计发生金额 | 占用资金余额 | 形成原因 | | | 现大股东 | | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | | 小计 | | | | | | | | | | | | | 前大股东 | | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-47 重庆智飞生物制品股份有限公司 第六届监事会第六次会议决议公告 二、监事会会议审议情况 经过认真审议，本次会议形成了如下决议： 1、审议通过了《<2025 年半年度报告>及<2025 年半年度报告摘要>》 经审核，监事会认为：董事会编制和审核公司 2025 年半年度报告及摘要的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容详见当日发布在中国证监会指定信息披露网站巨潮资讯网的公司 《2025 年半年度报告》及《2025 年半年度报告摘要》。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会于 2025 年 8 月 6 日以电子邮件的方式向监事发出通知。 2、本次会议于 2025 年 8 月 15 日 11:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的监事 3 人，实际出席并参加表决的监事 3 人。 4、本次会议由公司监事会主席荀 ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-46 重庆智飞生物制品股份有限公司 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会于 2025 年 8 月 6 日以电子邮件的方式向董事发出通知。 2、本次会议于 2025 年 8 月 15 日 10:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的董事 9 人，实际出席并参加表决的董事 9 人。 4、本次会议由公司董事长蒋仁生先生主持，公司监事、高级管理人员列席 了本次会议。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件及公司章程的规定。 二、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： 1、审议通过了《<2025 年半年度报告>及<2025 年半年度报告摘要>》 公司《2025 年半年度报告》及《2025 年半年度报告摘要》的编制程序符合 法律、法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了公司 的实际经营情况。 具体内容详见 ...

重庆智飞生物制品股份有限公司 2025 年半年度报告全文 重庆智飞生物制品股份有限公司 2025 年半年度报告 2025 年 8 月 1 重庆智飞生物制品股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人蒋仁生先生、主管会计工作负责人李振敬先生及会计机构负 责人(会计主管人员)蒋彩莲女士声明：保证本半年度报告中财务报告的真 实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 报告期内，受民众接种意愿下降、市场需求变化等多重因素影响，公司 业绩显著承压，主要产品的市场推广销售工作未达预期。此情况与疫苗行业 上市公司整体业绩下行趋势一致。公司积极应对挑战，多措并举逐步化解风 险，有效保障了经营稳定，实现了平稳发展。 尽管行业短期承压，但在政策支持与技术创新的驱动下，中国疫苗市场 仍蕴藏巨大发展潜力与商业机遇。公司坚定不移走自主创新道路，布局丰富 多元的自主产品在研管线，加大科研创新投入与资源整合力度，以实现创新 技 ...

Group 1 - The stock price of Zhifei Biological Products Co., Ltd. (300122.SZ) decreased by 4.05%, closing at 22.76 yuan [1] - Zhifei's stock reached an all-time high of 231.19 yuan on May 17, 2021 [1] - Research analyst He Wei from Dongfang Caifu Securities maintained an "overweight" rating for Zhifei Biological in a report dated April 29, 2021, highlighting the dual drivers of self-research and agency [1]

Group 1 - The core viewpoint of the news is that Chongqing Zhifei Biological Products Co., Ltd. has experienced a significant decline in revenue and profit in the latest quarterly report, indicating potential challenges for the company moving forward [1][3] - As of August 13, 2025, the company's stock price closed at 23.72 yuan, with a 1.89% increase and a trading volume of 553,700 hands, amounting to 1.308 billion yuan in transaction value [1] - The net inflow of main funds today was 66.56 million yuan, accounting for 5.09% of the transaction amount, with large orders contributing significantly to this inflow [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 2.374 billion yuan, a year-on-year decrease of 79.16%, and a net profit attributable to shareholders of 305.14 million yuan, down 120.93% year-on-year [1] - The company has a current ratio of 2.298, a quick ratio of 1.029, and a debt-to-asset ratio of 36.85%, indicating its liquidity and financial stability [1] - Chongqing Zhifei Biological has made investments in 9 companies, participated in 1,170 bidding projects, and holds 34 trademarks and 81 patents, along with 63 administrative licenses [2]

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd. has achieved a significant breakthrough in the influenza vaccine sector with the launch of its quadrivalent influenza virus split vaccine, marking the first vaccination in Hefei, Anhui Province, which enhances the domestic influenza vaccine market supply and strengthens the company's capabilities in infectious disease prevention [1][3]. Group 1: Vaccine Launch and Impact - The quadrivalent influenza vaccine is designed for individuals aged 3 and above and is produced using WHO-recommended influenza virus strains, showcasing good safety profiles [5]. - The vaccine's introduction provides more options for the public, particularly benefiting high-risk groups such as infants, the elderly, pregnant women, and patients with chronic diseases, thereby improving vaccine accessibility and public health in Hefei [3][5]. Group 2: Research and Development Pipeline - Zhifei Biological has a robust pipeline of influenza vaccines, including a quadrivalent split vaccine for children and a trivalent split vaccine, both of which are in the application review stage for market approval [5]. - The company is also advancing several other vaccine candidates, including a quadrivalent split vaccine with adjuvant in clinical trials and a trivalent split vaccine that has received clinical approval [5][6]. Group 3: Innovation and Future Prospects - The development of the influenza vaccine is part of Zhifei Biological's broader commitment to innovation, with multiple vaccine candidates in various stages of development, including rabies, pneumonia, and meningitis vaccines [6]. - The company has established research and production bases in Beijing, Anhui, and Chongqing, along with an innovation incubation center, to enhance its capabilities in vaccine and biopharmaceutical development [7].

Group 1 - The National Vaccine and Biotechnology Index (980015) rose by 1.92% as of August 13, 2025, with significant gains from constituent stocks such as Zhaoyan New Drug (603127) up 9.16%, Changshan Pharmaceutical (300255) up 7.86%, and WuXi AppTec (603259) up 7.24% [1] - Zhifei Biological's subsidiary achieved a major breakthrough by completing the first nationwide vaccination of its quadrivalent influenza vaccine in Hefei, Anhui Province [1] - Haitong International Securities noted that while overseas revenue for Chinese vaccine companies remains relatively low, more companies are actively expanding into international markets, with a steady increase in the number of vaccine product pre-certifications [1] Group 2 - The top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) as of July 31, 2025, include Fosun Pharma (600196), Changchun High-tech (000661), and Zhifei Biological (300122), collectively accounting for 64.94% of the index [2] - The Vaccine ETF Penghua (159657) closely tracks the National Vaccine and Biotechnology Index, which consists of 50 companies involved in the biotechnology industry, reflecting the overall performance of quality listed companies in the sector [1]

Core Viewpoint - Zhifei Biological has achieved a significant breakthrough in the influenza vaccine sector with the successful administration of the first dose of its quadrivalent influenza virus split vaccine in Hefei, Anhui Province, marking a milestone in its independent research and development efforts [1][3]. Group 1: Product Development and Market Position - The quadrivalent influenza vaccine is based on virus strains recommended by the World Health Organization and is suitable for individuals aged 3 and above, demonstrating good safety through its production process [3]. - The company has multiple self-developed products in the influenza vaccine field, including a quadrivalent split vaccine for children and a trivalent split vaccine, which are currently under review for market approval [4]. - Zhifei Biological has established three major research and production bases in Beijing, Anhui, and Chongqing, along with an innovation incubation center, enhancing its capabilities in vaccine development and production [3]. Group 2: Research and Development Investment - In 2024, the company plans to invest 1.391 billion yuan in research and development, increasing its R&D personnel to 1,072, with a total R&D investment of nearly 6 billion yuan over the past three years [3]. - The company is focused on addressing national public health needs and has several vaccine products in various stages of development, including clinical trials and market approval processes [4]. Group 3: Global Expansion and Clinical Trials - Zhifei Biological's self-developed products have been exported to dozens of countries, with clinical or registration work ongoing in nearly 20 countries [4]. - The company is advancing multiple new vaccine varieties, including a freeze-dried human rabies vaccine and a 15-valent pneumococcal conjugate vaccine, which are in the market review stage [4].